Healthcare Stocks Move in Wednesday's After-Market Session: Gainers and Losers

Healthcare stocks moved significantly in Wednesday's after-market session. Gainers included Adial Pharmaceuticals (ADIL), SeaStar Medical Holding (ICU), Aditxt (ADTX), Vor Biopharma (VOR), Unicycive Therapeutics (UNCY), and Plus Therapeutics (PSTV). Losers included Reviva Pharmaceuticals (RVPH), ZyVersa Therapeutics (ZVSA), Aethlon Medical (AEMD), XTL Biopharmaceuticals (XTLB), 60 Degrees (SXTP), and Evaxion (EVAX).

Healthcare stocks experienced significant fluctuations during Wednesday's after-market session. Notable gainers included Adial Pharmaceuticals (ADIL), SeaStar Medical Holding (ICU), Aditxt (ADTX), Vor Biopharma (VOR), Unicycive Therapeutics (UNCY), and Plus Therapeutics (PSTV). Conversely, Reviva Pharmaceuticals (RVPH), ZyVersa Therapeutics (ZVSA), Aethlon Medical (AEMD), XTL Biopharmaceuticals (XTLB), 60 Degrees (SXTP), and Evaxion (EVAX) were among the losers.

Adial Pharmaceuticals (ADIL) saw a notable rise, with the company announcing strategic collaborations for the production of AD04, its lead investigational drug for the treatment of Alcohol Use Disorder (AUD). The company signed agreements with Thermo Fisher Scientific and Cambrex, securing drug substance and drug product supply [1]. This move supports the completion of upcoming clinical trials and the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA).

Tenet Healthcare (THC) also closed the day at $171.52, moving +1.42% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 1.11%, while the Dow and Nasdaq saw increases of 1.19% and 1.43%, respectively. Market participants will closely follow the company's upcoming earnings release on July 22, 2025, with forecasted earnings per share (EPS) of $2.84, indicating a 22.94% upward movement from the prior year. The company is projected to report net sales of $5.15 billion for the quarter, a 0.85% increase from the year-ago period [2].

Investors should monitor recent adjustments to analyst estimates for Tenet Healthcare, as positive revisions can indicate a favorable business outlook. The Zacks Rank system, which considers estimate changes, provides a simple, actionable rating system. As of now, Tenet Healthcare holds a Zacks Rank of #3 (Hold), with a Forward P/E ratio of 13.29, trading at a premium to its industry average of 11.11.

References:
[1] https://www.biospace.com/press-releases/adial-pharmaceuticals-secures-u-s-based-manufacturing-through-agreements-with-cambrex-and-thermo-fisher-scientific-for-drug-substance-and-drug-product-supply
[2] https://finance.yahoo.com/news/tenet-healthcare-thc-rises-higher-221504091.html